Colonial River Investments LLC Invests $441,000 in Natera, Inc. (NASDAQ:NTRA)

Colonial River Investments LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 3,122 shares of the medical research company's stock, valued at approximately $441,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. LRI Investments LLC purchased a new position in Natera in the 4th quarter worth approximately $29,000. Rakuten Securities Inc. lifted its holdings in shares of Natera by 117.8% during the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC purchased a new position in Natera in the first quarter worth $32,000. EverSource Wealth Advisors LLC increased its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Principal Securities Inc. raised its position in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 6,980 shares of the business's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00. Following the sale, the chief executive officer directly owned 185,182 shares of the company's stock, valued at $27,795,818.20. The trade was a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Solomon Moshkevich sold 3,000 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total value of $471,210.00. Following the completion of the sale, the insider owned 133,205 shares in the company, valued at $20,922,509.35. The trade was a 2.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,630 shares of company stock worth $6,235,808 over the last three months. Company insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of NTRA traded down $8.22 on Tuesday, reaching $160.72. The stock had a trading volume of 1,323,970 shares, compared to its average volume of 1,421,070. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The firm has a market capitalization of $21.95 billion, a price-to-earnings ratio of -109.33 and a beta of 1.74. The company has a 50-day simple moving average of $159.46 and a 200-day simple moving average of $158.49.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company's quarterly revenue was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.56) EPS. On average, analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of several recent research reports. UBS Group increased their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research report on Friday, May 9th. Royal Bank Of Canada assumed coverage on shares of Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. Piper Sandler boosted their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Finally, Morgan Stanley lifted their price objective on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $184.63.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.